Research progress on vaccines against human respiratory syncytial virus
10.13200/j.cnki.cjb.003844
- VernacularTitle:人呼吸道合胞病毒疫苗的研究进展
- Author:
ZHOU Hongjun
- Publication Type:Journal Article
- Keywords:
Human respiratory syncytial virus(hRSV);
Attenuated live vaccine;
Subunit protein vaccine;
Vector vaccine
- From:
Chinese Journal of Biologicals
2023;36(3):379-
- CountryChina
- Language:Chinese
-
Abstract:
Human respiratory syncytial virus(hRSV)is one of the main pathogens that cause lower respiratory tract infection in infants and the elderly.hRSV genome contains 10 genes with a full length of 15 222 bp,encoding 11 proteins(9structural proteins and 2 non-structural proteins).Different proteins play different roles in the pathogenesis of hRSV.With the in-depth research on the biological and structural characteristics of hRSV,various types of hRSV vaccines have been developed,making rapid progress.For example,hRSV attenuated live vaccine hRSV ?NS2/?1313/I1314L has entered Phase II clinical trial,and hRSV subunit protein vaccine Pre-F-GCN4t has entered Phase III clinical trial.In this paper,the biological characteristics of hRSV and the types of hRSV vaccines with rapid progress are reviewed so as to provide a reference for the development of hRSV vaccines in China.
